Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01497184Phase 1Completed

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

Role: collaborator

NCT02529813Phase 1Completed

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Role: collaborator

NCT03579888Phase 1Terminated

CD19-Specific T Cells Post AlloSCT

Role: collaborator

All 3 trials loaded